Thanks for pledging! - Share this with your friends
Thank you for your pledge! We'll be in touch once the campaign meets its goal, and again when it closes, so you know we'll be charging your card.
CDA Health Pty Ltd
I want to embed this investment somewhere
107 people pledged
22 days left
AU$500,000 minimum target
Pledges will only be confirmed if the target is reached by: 15/06/2019 at 12:00 AM (AEST)Make a Pledge
CDA Health Pty Ltd
CDA Health Pty Ltd is offering fully paid ordinary shares at $1 per share to raise a maximum of $2,000,000
This Offer is made under the CSF regime in Part 6D.3A of the Corporations Act 2001 (Corporations Act). The general public in Australia can buy up to $10,000 worth of shares in this company, as part of the new equity crowdfunding legislation (Note: there is no cap on how much Sophisticated Investors can invest). Please make sure to read the risk warning statement, offer document, and understand the Cooling-Off rights. Instructions on how to register to invest and pledge are here.
The key terms and conditions of the crowd-sourced funding Offer are set out in the Table below.
When you buy shares in CDA Health you are making an investment into all four of our subsidaries within the rapidly growing Medical Cannabis and Hemp industries. The shares you purchase result in owning a percentage of the company and if CDA Health increases in value, your shares do too.
In the future there is the potential for us to go through an initial public offering on a relevant stock exchange, a merger or sale to another company, or a share buyback from the company which are the usual exit events which could allow you to realise your investment.
A LETTER FROM DR BEN, OUR FOUNDER & CHAIR
Thank you for your interest in investing in our company, CDA Health Pty Ltd. We’re proud to invite you to be part of Australia’s first ever Equity Crowdfunded Medical Cannabis investment opportunity.
Prior to Australia prohibiting Cannabis under federal law in 1926, Cannabis was widely used as a medicine dating back 5,000 years. Once again Cannabis has been made available to the general public, with its legal status for medical prescription being reinstated by the Australian Federal Government in 2016.
My personal involvement in medical cannabis began when I learned that the United States Department of Health patented Cannabis compounds as “antioxidants and neuroprotectants’’ in 1998. Prior to discovering this information, my mother had passed away from a rare degenerative brain condition. The rapid onset of this disease was traumatic for our family. And although the disease was neurological, we witnessed more lucid moments from her than I care to remember. My sister Jess will never forget having to take away mums car keys and install an internal door lock to stop her from wandering into the streets. The brain degeneration significantly affected her quality of life and after only 3 years from diagnosis she required 24hr care and assistance. I believe her pain and suffering would have reduced and her life potentially prolonged had we known the US patent existed and had legal access to the neuroprotective properties of Cannabis.
After entering a period of research I discovered many convincing case reports containing phenomenal stories from patients who had survived their illnesses through use of the plant. We uncovered one particular case study that involved lab animals suffering from heart attacks. After being injected with Cannabidiol (CBD), these animals showed a 66% reduction in the magnitude of their heart attacks.
Since 2016, following the re-legalisation of Medical Cannabis, we have been striving to ensure no one will ever have to suffer unnecessarily like my mother did. By 2017, we had proudly founded Burleigh Heads Cannabis Pty Ltd (BHC), which was granted one of Australia’s first Medical Cannabis wholesaling Licences.
Recent reports suggest there are more than 200,000 Australians accessing black-market Cannabis for medicinal purposes, yet only a few thousand have accessed it legally to date. However, the growing awareness and education of both patients and doctors has resulted in legal access rapidly increasing.
Cannabis Doctors Australia Pty Ltd (CDA) was founded by us, a family of doctors and professionals, to streamline the complex process of accessing Medical Cannabis. We’re dedicated to training doctors on the efficacy of Medical Cannabis and how to prescribe the medicine safely and efficiently. Since October 2018, we’ve provided over 1,500 prescriptions to more than 700 patients, which equates to almost a third of the SAS B approvals granted since our launch.
Our first CDA clinic opened in Miami on the Gold Coast, before expanding to further affiliate clinics on the coast, then Melbourne, and Brisbane. The number of our clinics is growing as more doctors approach us about our services. Additionally, to make Medical Cannabis available to all Australians, our doctors provide TeleHealth consultations to every state and territory within the country.
Despite only having opened our doors to patients 6 months ago our waiting lists continue to grow with our flagship clinic in the Gold Coast now out to 9 weeks. The CDA group broke even in February 2019 and continues to make profit gains; few other Australian Medical Cannabis companies have been able to achieve this.
By integrating both the service and product-supply aspect within our business model, we are able to stay aligned with our core values of providing safe, reliable and affordable access to Medical Cannabis now and into the future.
As a family-owned company independent of Big Pharma, with a team of medical professionals, we have set ourselves apart from the multinationals invested in the Cannabis market. We intend to continue our strong focus on patient health, while simultaneously implementing a staged growth plan for the business.
During our time in the Australian Medical Cannabis industry, we have gained a deep understanding of the market landscape. CDA is helmed by doctors who have seen first-hand the positive results of Medical Cannabis for many patients.
Your interest in investing in our company comes at a time of rapid expansion in the Australian Cannabis industry, which is estimated to grow to $3 billion by 2028.
With an eye to the future, we will continue to anticipate regulatory and industry changes, while positioning ourselves as Australasia’s go-to Medical Cannabis provider. We are extremely excited for the future of CDA and welcome you to join us on this journey of pioneering a shift towards safer plant-based medicines.
Kind regards and we hope to welcome you to the CDA family,
Dr Ben Jansen
FRACGP FRNZCGP FRNZCUCP
BHB MBChB PGDipSM PGDipCEM
OVERVIEW OF THE COMPANY AND ITS SUBSIDIARIES
We aim to become the leading patient-focused Medical Cannabis Organisation in Australasia.
CDA Health Pty Ltd (the Company) is the parent company of the Group. The Company, through its subsidiaries, Burleigh Heads Cannabis Pty Ltd (BHC), Cannabis Doctors Australia Pty Ltd (CDA) and Cannabis Doctors Aotearoa Limited (CDANZ), offers a clinical service alongside a product supply chain.
BHC is a fully licensed wholesaler and offers a market entry solution to local and international manufacturers and cultivators seeking to gain access to the Medical Cannabis industries in Australia and New Zealand.
Our clinical arm CDA provides efficient, affordable and easy service for patients requiring Medical Cannabis access approvals. CDA operates doctor-led Medical Cannabis clinics along with an Australia-wide TeleHealth consultation service whereby patients can consult from the comfort of their own home.
CDA is one of the first (possibly the only) Medical Cannabis groups to pass the key milestone of 1000 patient approvals and 1500 prescriptions, since launching in October 2018.
The clinical model is run by CDA’s internal doctors and external affiliate doctors who have been chosen to undergo the CDA training program. The training involves the education of all regulatory and compliance considerations, familiarisation with the consultation and application processes and a series of templates that our in-house doctors have developed.
Patients are engaged via our CDA Clinical brand. Once a patient has registered on our website a CDA customer service representative will personally call the patient for a free eligibility screening and to answer any questions that the patient might have. This builds trust into the CDA brand and allows a high level of care in the initial engagement phase before patients are referred out to one of the affiliate clinics.
Cannabis Doctors Aotearoa Limited (CDANZ) was established to leverage New Zealand’s less stringent legislation, whereby doctors can prescribe Medical Cannabis to patients without the need for complex approvals. CDANZ utilises the same patient-focused clinical model as CDA Clinics to enable international growth of the CDA Brand.
CDANZ will provide operational and technical knowledge as well as intellectual property to pharmacies and affiliate doctors within our network that are currently seeking access to Medical Cannabis. Operational planning is already underway and we aim to provide NZ patients with the same, trusted service and products by June 2019.
The final subsidiary, Healthy Not High Pty Ltd (HNH), completes the product offering. HNH is a hemp food and nutraceuticals brand that aims to have sustainable Australian-grown hemp products sold online and in-store by mid-2019. The subsidiaries are all wholly owned by the Company, apart from BHC which is 90.9% owned by the Company.
Burleigh Heads Cannabis (BHC) is a fully licensed Medical Cannabis wholesaler. BHC utilises its secure temperature-regulated storage facility on the Gold Coast and national pharmacy partner network to provide local and international producers with streamlined importation and distribution services throughout Australia. BHC has seen strong growth in sales revenues since the period commencing October 2018.
Healthy Not High Pty Ltd (HNH) is a hemp food and nutraceuticals company based on the Gold Coast. The brand expands the group’s umbrella to leverage the rapidly growing hemp market in Australia. HNH’s aim is for consumers to be able to access quality products from Australian-grown hemp via retail outlets and online sales. Both manufacturing (contract) and distribution is in place and products are due for release into the market by mid-2019.
The Company is embarking on an equity raise offer through crowdfunding, with a goal to remain a strong, adaptive and independently owned mainstay of the Australian Medical Cannabis industry.
This is an investment opportunity for you to own a piece of a progressive patient-focused Medical Cannabis Company that aims to change the paradigm of healthcare in Australasia.
OUR WHY & OUR PURPOSE ARE CENTRAL TO OUR BRAND
We believe everyone has a right to access safe and affordable plant-based medicines.
To put it simply, each of the founding shareholders and directors emphatically believes in the therapeutic and medicinal properties of Medical Cannabis. We consider it our mission to make affordable, high-quality products available to patients who need Medical Cannabis.
WHY ARE WE EQUITY CROWDFUNDING?
We want to deliver our company objectives without compromising our principles in the pursuit of short-term profit.
Through Equity Crowdfunding we’re offering patients, doctors, advocates and retail investors the opportunity to share in the Company’s journey into the future.
We want to give everyday Australians and sophisticated investors an opportunity to be part of our business. By offering Equity to like-minded people in our community, we look to remain independent from Big Pharma.
We’re thrilled to be offering you a chance to join our company. You can help us continue to provide compassionate care for people in need by owning a piece of the rapidly growing Medical Cannabis market.
KEY MILESTONES TO DATE OF CDA AND ITS SUBSIDIARIES
THE MARKET OPPORTUNITY
Global forecasts show legal Cannabis sales will reach USD $57 Billion by 2027, of which 33% (USD $18.8 Billion) will be Medicinal Cannabis
Australasia has a population of 29.8 million and Canada 37.2 million, therefore, we will look to Canada as a similar model when making market assumptions. The number of patients accessing Medical Cannabis in Canada grew rapidly over a three-year period, and now totals well over 300,000 patients, while continuing to grow despite recreational legalisation which puts less reliance on doctor approvals and prescriptions.
As of March 2019, there were less than 6,000 active Special Access Scheme B Medicinal Cannabis approvals in Australia. Recent SAS approval growth has recently seen an average rate of 29% per month in 2019, and it is estimated to surpass 15,000 total approvals by the end of this year.
When the TGA relaxed rules around prescribing Medical Cannabis in October 2018, the total monthly patient numbers in Australia began increasing.
In April 2019, the Queensland Government (the state in which CDA and BHC are based) passed legislation to remove the requirement for patients to seek additional state approvals, which improves the prescription process significantly.
NOTE: CDA Clinics first full operating month was November 2018 where we facilitated over 100 patient approvals.
We have established a proven business model with limited resources. We aim to capture a significant piece of the projected $3 billion market.
We believe that moving into our next phase of expansion provides a rare investment opportunity, whereby there is a chance to own a stake in an entirely new industry at an early stage in preparation for further growth.
HOW DO OUR COMPANIES WORK TOGETHER?
CDA receives a number of revenue streams via our storefront clinics and Australia-wide TeleHealth services, which include initial consultations, follow-up consultations, and 6-monthly renewal consultation fees. Moving forward, CDA aims to expand its consultation services through franchising the CDA Clinics brand and increasing its affiliate medical practitioner numbers for both In-Clinic and TeleHealth consultations.
2. PRODUCT WHOLESALING
BHC is able to import, store and supply Australian doctors and pharmacies with a diverse range of Medical Cannabis product types and brands. BHC is able to leverage its supplier status to provide CDA patients with a reliable resource of affordable quality products.
This unique set-up of the two subsidiaries allows us to subsidise product costs, which can be passed directly onto patients. It is our fostering of strong patient relationships that has formed a robust distribution avenue. This in turn has resulted in powerful buying opportunities with international partners. Diversifying puts us in a position to safeguard against industry reliability issues and price control, while scaling up both businesses on an integrated sliding growth scale.
OUR THREE-PHASE GROWTH STRATEGY
Our strategy is broken into three distinct phases. By progressing through these stages we’re able to operate more economically, while providing exceptional service to our patients.
OUR MANAGEMENT TEAM
Each and every member of the team at CDA Health believes in the healing power of Medical Cannabis. Each one of us is passionate about the industry and offer diverse skills and experience in our relative areas of expertise.
From left to right: Dr Ben Jansen, Guy Headley, Jessimine Jansen, Dr Matua Jansen
Dr Ben Jansen - Chairman & Clinical Director, FRACGP, FRNZCUCP, FRNZCGP, BHB, MBChB
Ben is a co-founder of Cannabis Doctors Australia and lecturer on Medicinal Cannabis. He is responsible for regulatory compliance and clinical operations within the Company.
Since 2005, Ben has worked as a Doctor of Medicine with three Medical College Fellowships. His primary background is in General Practice. As a result of Ben’s research, he is confident of bringing novel, innovative and profitable Medical Cannabis products to market in Australia and beyond.
Ben has been instrumental in designing the CanView™ platform, which once completed will increase efficiencies in the patient integration and monitoring process. This is expected to help unlock further opportunities for CDA growth.
Dr Matua Jansen - Managing Director, C.Hsc, BHB, MBCHB (Dist.), MBA
Matua is responsible for the Business Strategy, Risk Management and TeleHealth Operations.
Matua is a Doctor of Medicine with a Masters in Business Administration. Matua has spent almost a decade working in oncology for the largest private hospital provider in Australia, where as both a clinician and manager, he has seen the issues associated with opioid addiction. With his extensive network of business contacts, he is focused on developing key partnerships and customer relationships.
Guy Headley - Director of Operations
Guy is co-founder of Burleigh Heads Cannabis and Director of Operations.
Having been active in the Australian Medical Cannabis industry since 2016, Guy brings a wealth of knowledge to his role as CDA Director of Operations. Additionally, Guy has more than a decade of experience in the procurement negotiation.
Guy has utilised his professional standing to help build and maintain strong relationships in the global cannabis supply chain and domestic regulatory agencies to ensure Burleigh Heads Cannabis maintains a robust market presence.
Jessimine Jansen - Marketing Director, BAPsych, BAMedia&Comms, PGDipFilmProd
With over a decade of experience driving complex projects within large organisations such as Ernst & Young (EY), Sky TV and the Commonwealth Games 2018, Jessimine brings a diverse mix of business disciplines and perspectives.
Since committing to CDA in October 2018, Jessimine saw a need to connect busy doctors to the patient experience and was the driving force for the creation of CDA Clinics. Jessimine was also the mastermind behind the CanView™ platform.
With a passion for system efficiency and an analytical approach, Jessimine keeps a keen eye on expenditure and risk management. She achieves all of this while ensuring the business remains in touch with our most important aspect, our customers.
Stone Group Lawyers
Head Legal Counsel
Principal Nick Stone and Senior Associate Dan Birch, supported by a team of legal experts at Stone Group Lawyers, have a combined 20+ years’ experience across commercial, corporate and litigation practice areas. Both Nick and Dan have an active advisory involvement with the Company. They have proven experience guiding professional clients through commercial transactions to help them reach their full business potential.
Dr Cris Filipe-Alves, PHD, MSC, BSC, PGDIPSCICOM
Cris is currently the Director of Quality Assurance for Craft Cannabis BC. He has been active in the Canadian cannabis industry in roles of multimodal cannabis extraction, novel product formulation, research and development, laboratory design, guideline production, and scientific quality inspection. Cris brings his vast experience to CDA’s exclusive product manufacturing and beyond into GMP extraction.
Krish Rambishiwar, BPharm, RegPharm NZ, MPS
Krish is currently running a successful Pharmacy wholesale enterprise in New Zealand and has a comprehensive knowledge of contemporary New Zealand cannabis legislation. Krish has a passion for developing new pharmaceutical products and plays a key role in our New Zealand Expansion.
THE COMPETITIVE LANDSCAPE
CDA’s competitive advantage starts with our two sided, integrated business model which positions us uniquely in the market.
- We’ve removed ‘middlemen’ throughout the prescription-to-patient process. This not only increases patient affordability but fewer hands throughout this process could help maintain higher standards of quality and reliability
- We’re a doctor-led company, independent from big pharmaceutical companies and large international enterprises, which enables more flexibility within the market. Our ability to remain dynamic allows us to rapidly integrate the latest developments within the industry and focus on patient outcomes
- We are fully licensed to wholesale and are legally able to store all products in-house. We hope to move into manufacturing and cultivation, which, if we are able to do, will shift us from a prescription-to-patient process to a plant-to-patient process.
- Strong intellectual property and operating experience from both the doctor and product aspect
- Our focus on streamlined, personalised patient care allows our patients to remain informed and have more control over their medical journey, while fostering long-term relationships with our brand
Listed competitor comparison
The table below is a comparison with a suitable competitor that is listed on the Australian Stock Exchange. Please note the differences in line item dates that reflect the most current statistics publicly available.
- Column 1 shows the Competitors standing as at their IPO in September 2018,
- Column 2 shows their progress after capital raise and market growth for the first quarter of 2019.
- Column 3 data is current as at 31 March 2019 and shows CDA Health information for the same first quarter of 2019
Listed competitor comparison 1. Company Valuations
Listed competitor comparison 2. Company Financials
* Based on last quarter sales reported less expenses paid detailed in the company cashflow statement. Actual loss for the quarter may vary due to movements in accounting accruals.
Listed competitor comparison 3. Company Overviews
* all trademarks relevant to the Company and Group are held by the Company and available for use by the Subsidiaries by way of licence agreement. Where BHC acts as a distributor for imported products, BHC will obtain licences for the use of the relevant intellectual property.
** Quarterly update dated 4 April 2019, states that competitor accrued more than 100 patients in a month for the first time. It can be reasonably inferred that at the date of publication of their Offer document on 4 September 2018, there were under 100 patients per month.
As at the date of this CSF offer document, the Company has 17,872,340 Ordinary Class Shares on issue, with 17,157,447 fully paid and 714,893 partially paid ordinary shares on issue as set out below.
Issued capital pre and post offer (if successful and maximum raised)
*CDA Health Pty Ltd has entered into an Agreement with Stone Group Lawyers for a 3-year retainer to be paid for by the issue of shares in the Company. As part of that Agreement, Stone Group Lawyers may nominate shareholders to hold 6% of the issued shares in the company, post offer. Please refer to the offer document for further information on the agreement.
CDA Health is uniquely positioned in the Australian Medical Cannabis industry, already generating enough revenue to operate without external funding. This was shown by breaking even in February 2019, producing a total Net Profit of $36,967 in March 2019 and $78,396 in April 2019.
We are proud of what we’ve achieved with limited resources. However, we require funding to scale and meet our exponentially growing demand for goods and services. With the investment funds raised from this round we commit to continue operating in a lean, strategic manner.
Burleigh Heads Cannabis Pty Ltd began trading in January 2018, Cannabis Doctors Australia Pty Ltd (CDA Clinics) began trading in October 2018 and the group was consolidated into CDA Health Pty Ltd in early March 2019 which currently operates solely as a holding company.
Cannabis Doctors Aotearoa Limited and Healthy Not High Pty Ltd have secured key partnerships and are ready to commence trading, however, these entities have not yet generated any income and have incurred only nominal amortization expenses.
Below is a summary of the financial statements for the current financial year dated 1 July 2018 to 30 April 2019. A copy of the financial statements prepared by CDA’s accountants, MWM prepared in accordance with the Australian Accounting standards, is available in appendix 2 of the offer document.
An investment in the Company should be seen as high-risk and speculative. A description of the main risks that may impact our business is included in our offer document. Investors should read this section carefully before deciding to apply for shares under the Offer. There are also other, more general risks associated with the Company (e.g. risks relating to general economic conditions or the inability to sell our shares).
TERMS OF THE OFFER
CDA Health is offering up to 2,000,000 fully paid ordinary shares at an issue price of $1.00 per share to raise up to $2,000,000.
- Cooling-off Rights - You have the right to withdraw your pledge for any reason (including if you change your mind about investing in the Company). You must do so within five business days of making your application (the Cooling-off Period) by emailing [email protected] with your full legal name and number of shares you pledged for.
- Communication Facility for the Offer - You can ask questions about the Offer on the Question tab above.
- Effect of the Corporate Governance Concessions - There are some concessions around the Annual Report, Takeovers and Related Party Transactions.
USE OF FUNDS
Over the past two years the team at CDA has gained an in-depth understanding of what is required to succeed in Australasia’s Medical Cannabis market.
Receiving maximum investment and implementation of our 2019 strategy will underpin CDA Health’s status of being a strong leader in the Medical Cannabis industry throughout the Australia-Pacific region. CDA will thereby be in a position to capitalise on our first mover advantage and garnish attractive opportunities, such as mergers, acquisitions or listing on a relevant stock exchange.
The table below sets out the intended use of funds raised under this Offer, based on the minimum and maximum subscription amounts.
Manufacturing Capabilities ($0 min - $300,000 max)
- Applications at state and federal levels for a manufacturing licence will commence immediately, to coincide with an application to the TGA for a Good Manufacture Practice (GMP) certification upon successful fundraising.
- If our maximum goal is met, we aim for construction of facilities to begin before the end of 2019.
- If we do not meet our maximum funds raised, we intend to implement construction at a later date using company revenues.
Sales and marketing ($50,000 min - $155,000 max)
- Affiliate Doctor Education and Onboarding - The team at CDA intends to increase the number of educated prescribing doctors in Australia and will dedicate resources to help reach this goal. Sales and marketing costs include the expansion and implementation of our affiliate clinics and doctor program.
- New Zealand Expansion - If our maximum is reached, we intend to allocate resources into onboarding and educating our existing doctor network. This will position CDA as a first mover in the local Medical Cannabis industry and help accelerate our entry into the New Zealand market.
Information Technology (IT) investment ($50,000 min - $170,000 max)
- Minimum goal - automate internal processes in order to improve time resources, scalability and client relationship management.
- Maximum goal - development and implementation of our CanView™ platform.
Working Capital ($367,000 min - $1,200,000 max)
- Purchase further wholesale orders.
- Overhead costs, such as rent and admin expenses, as maximum raise will allow additional physical clinics to open.
Employment of key staff. We will commence recruitment for the following positions:
Business Development Manager
Patient Care Managers
- Provide working capital to carry out the Group’s business objectives as determined by the Directors.
Director and senior manager remuneration. Our management team so far has been working on reduced compensation.Therefore, based on the amount of money raised, we aim to increase salary to be more aligned with market rates. This can be found under 3.2 Use of funds in the offer document.
Offer costs ($33,000 min - $123,000 max)
The costs of the Offer include the Intermediary’s fees under the hosting agreement between the Company and the Intermediary. These fees are 6% including GST on the total amount raised plus an application and onboarding fee of $3,000 including GST.
Other than as specified above, no other payments from the funds raised will be paid (directly or indirectly) to related parties, controlling shareholders, or any other persons involved in promoting or marketing the Offer.
Long-term Additional Funding Requirements
We expect that the Maximum Subscription amount will be sufficient to meet the Company’s Phase 2 objectives.
If only the Minimum Subscription amount is raised, the Company may require further funding to be able to carry out our intended activities over the next 12-18 months.
In such circumstances, the Company may consider undertaking a further crowd-sourced funding (CSF) offer under the crowd-sourced funding regime. Until additional funding is obtained, we may need to scale back sales and marketing and production activities and continue to focus our cash resources on improving cash flow through our core business activities, which encompass both clinics and wholesale.
NOTE FROM PLEDGEME
- PledgeMe have completed background checks on the Company (CDA Health Pty Ltd) and its Directors (Ben Jansen, Matua Jansen, Guy Headley and Jessimine Jansen). We found no adverse findings in our checks. Please read the warning statement, offer document and ask questions before investing.
- PledgeMe will receive 6% (GST inclusive) of the funds raised if the goal is met by the deadline.
1 week: 50% funded, 101 investors
23/05/2019 at 4:47 PM
1 week, 50% funded, 101 investors
Today marks exactly 1 week since we launched Australia's first Medical Cannabis Equity Crowdfunding campaign.
We want to thank those who have pledged to buy shares so far and remind everyone who is still following along that in order for shares to be successfully issued, we do need to hit our minimum of $500,000.
Of course, this is something we would like to secure sooner rather than later.
Tonight: We’ll answer all investment questions
We've been getting a large number of queries coming through about how the crowdfunding part of the investment works and have spoken to a lot of people who are holding off investing until they learn a bit more.
So, tonight we'll be holding a Facebook Live event with the Founder of the PledgeMe platform, Anna Guenther where we'll be discussing a range of topics including the following:
What is equity crowdfunding?
Who can invest?
How do I invest?
When does my money come out of my account?
What do investors get?
What is a sophisticated investor?
What is my return on investment?
What are the investor benefits?
What are CDA's future plans?
This will run for approximately 45 minutes on the CDA Clinics Facebook Page and will be highly valuable for those who need a bit more clarity on how everything works.
Why this investment is so important…
A lot of patients are in need of Medical Cannabis products as soon as possible and the staggering number of stories from those who have battled with opioid side effects, addiction or negligible results is what makes it critical for us to expand to be able to cater for the 300,000 potential patients.
Benefits CDA will bring to Australia & patients are:
1. Give Australian’s a voice in the trajectory of this new Healthcare industry
2. Give patients immediate access to a specialised doctor to get a prescription
3. Bring product costs down significantly. Below current black market rates.
4. Boost of the Australian economy through local job creation and community investment.
5. Ensuring patients and doctors have safe, reliable access to Medical Cannabis products
6. Increase the number of doctors who feel comfortable prescribing Medical Cannabis
The 2 key outcomes from this investment
- With manufacturing capabilities we will be able to bring costs down by over 40% of the current average prices on the market right now.
- With further doctors we will be able to bring wait times down from 9 weeks to 5 days and be prepared to cater for the expected 15,000 Australian patients by the end of this year.
Your actions can help make these benefits a reality for as little as $250. With that you're able to own a percentage of our company and if CDA Health increases in value, your shares do too.
We’re excited to announce...
Today Vivo Cannabis, a Canadian company listed on the Toronto Stock Exchange, and Burleigh Heads Cannabis signed a distribution agreement to increase the ability of Australian patients to access high-quality Medical Cannabis flower and oils.
This is a testament to the strong CDA supply chain which aims to provide patients with the largest and most affordable product range in Australia, and showcases it's continued ability to provide a market entry solution for international businesses wanting to access Australia's rapidly growing Medical Cannabis market.
Below are the links that can be shared through email and Facebook etc which for every new person that sees it, gives us another potential investor to get us closer to the goal!
We thank you once again for your support and look forward to growing CDA Health together.
You need to pledge to see this update.
You need to pledge to see this update.
|Maximum Shares Offered||2,000,000|
(application/pdf, 2.28 MB, uploaded 13 May 2019)
(application/pdf, 513 KB, uploaded 20 May 2019)
|Dr. Ben Jansen||Chairman & Clinical Director||https://www.linkedin.com/in/dr-ben-jansen-a9126516b||✔|
|Dr. Matua Jansen||Managing Director||https://www.linkedin.com/in/matua-jansen-743782104/||✔|
|Guy Headley||Director of Operations||https://www.linkedin.com/company/cannabis-doctors-australia/||✔|
|Jessimine Jansen||Marketing Director||https://www.linkedin.com/in/jessimine-jansen-62187440/||✔|
Ask a Question (You must login to ask a question)
In the warning statement, it states "Your investment is unlikely to be liquid. This means you are unlikely to be able to sell your shares quickly or at all"
Is this just in the initial set up stage? Will you be able to in years to come, if you wish, cash in and sell your shares??
This is the standard risk warning statement required for all equity crowdfunding campaigns.
You could privately sell your shares however they will not be traded on a secondary market which is why there is low liquidity.
In years to come, there is the potential for an initial public offering on a stock exchange, a merger or sale to another company or a share buyback from the company which are the usual exit events which could allow you to realise the investment.
Thanks for considering investing with us,
The CDA team.
Answered on 17-05-2019 by Cannabis Doctors Australia
Identity verification...As an "other" form of ID, all Utility Bills, Bank or Credit Card statements etc have only my PO Box as my address, not my residential address as I live on a property and have no mail delivered here. Is this a problem?Posted on 16-05-2019 by Kathryn
Does CDA/BHC have any involvement with Cannvalate?Posted on 18-05-2019 by Beau Evans
Are there any investor perks?Posted on 22-05-2019 by phillip mulligan
Hi Phillip, appreciate the question. As much as we would love to give out free samples, we are unfortunately restricted due to the nature of the regulated industry. What we can ensure is that everyone who invests in CDA Health during this campaign will play an integral part of the mission to increase access to Medical Cannabis, bring down product costs and reduce the amount of opioid usage for our patients. This will directly improve the quality of life for thousands of people around Australia. Hopefully this works as an impactful perk!
Answered on 23-05-2019 by Cannabis Doctors Australia
Followers of CDA Health Pty Ltd
2019-05-23 20:43:10 +1000
2019-05-23 20:25:40 +1000
"Pledge done... as an ex defence person suffering from a few problems I think this is long over due... "
2019-05-23 19:54:54 +1000
2019-05-23 19:41:26 +1000
2019-05-23 19:07:20 +1000
"Had to round it off to a nice even 250k"
2019-05-23 18:17:42 +1000
2019-05-23 14:51:21 +1000
2019-05-23 10:33:18 +1000
2019-05-23 08:45:27 +1000
"Good Luck team - glad I have the opportunity to get in at grassroots level and looking forward to being on the journey"
2019-05-23 08:12:59 +1000
2019-05-23 06:43:11 +1000
2019-05-22 21:27:41 +1000
2019-05-22 20:15:49 +1000
2019-05-22 17:33:23 +1000
2019-05-22 14:40:01 +1000
2019-05-22 13:00:26 +1000
"Go get em tiger."
2019-05-22 10:43:03 +1000
"Looking forward to the future. Good luck! "
2019-05-21 13:44:16 +1000
2019-05-21 13:44:06 +1000
2019-05-21 12:52:05 +1000
2019-05-21 02:38:24 +1000
2019-05-20 13:20:13 +1000
2019-05-20 07:53:53 +1000
2019-05-20 07:29:00 +1000
2019-05-19 19:35:36 +1000
2019-05-19 12:01:42 +1000
2019-05-19 10:57:54 +1000
2019-05-19 10:31:53 +1000
2019-05-18 16:31:18 +1000
2019-05-18 13:00:37 +1000
"Thank you for offering this opportunity.. "